These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 27435455

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Quantitative prediction of the extent of drug-drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes.
    Iwasaki S, Hirabayashi H, Amano N.
    Xenobiotica; 2018 Aug; 48(8):770-780. PubMed ID: 28851254
    [Abstract] [Full Text] [Related]

  • 3. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
    Iwasaki S, Kosugi Y, Zhu AZX, Nakagawa S, Sano N, Funami M, Kosaka M, Furuta A, Hirabayashi H, Amano N.
    Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
    [Abstract] [Full Text] [Related]

  • 4. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K.
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [Abstract] [Full Text] [Related]

  • 5. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K, Yamamoto K, Kotaki H, Sawada Y, Iga T.
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [Abstract] [Full Text] [Related]

  • 6. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats.
    Kishimoto W, Takano J, Senda C, Ishiguro N, Sakai K, Igarashi T.
    Biol Pharm Bull; 2000 Sep; 23(9):1027-32. PubMed ID: 10993198
    [Abstract] [Full Text] [Related]

  • 7. Characterization of 1-Aminobenzotriazole and Ketoconazole as Novel Inhibitors of Monoamine Oxidase (MAO): An In Vitro Investigation.
    Shaik AN, LeDuc BW, Khan AA.
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):827-834. PubMed ID: 28185143
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [Abstract] [Full Text] [Related]

  • 10. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T.
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
    Lehtinen T, Tolonen A, Turpeinen M, Uusitalo J, Vuorinen J, Lammintausta R, Pelkonen O, Scheinin M.
    Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
    Palacharla RC, Uthukam V, Manoharan A, Ponnamaneni RK, Padala NP, Boggavarapu RK, Bhyrapuneni G, Ajjala DR, Nirogi R.
    Eur J Pharm Sci; 2017 Apr 01; 101():80-89. PubMed ID: 28179134
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
    Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.
    J Pharmacol Exp Ther; 2010 Feb 01; 332(2):562-8. PubMed ID: 19889796
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.